WASHINGTON — The Food and Drug Administration will relax its review of some genetic tests that examine millions of different variants at the same time, the agency announced Thursday.
So far, the FDA has not approved any of these broad “next-generation sequencing” tests, but as their cost drops, the agency believes they have more potential to help patients.
